Crossmark

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy

Crossref DOI link: https://doi.org/10.1007/s00408-024-00742-x

Published Online: 2024-09-06

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Söllner, Julia F.

Bentink, Stefan

Hesslinger, Christian

Leonard, Thomas B.

Neely, Megan L. https://orcid.org/0000-0002-0101-1081
Patel, Nina M.

Schlange, Thomas https://orcid.org/0000-0002-2027-3976
Todd, Jamie L. https://orcid.org/0000-0003-4247-3693
Vinisko, Richard

Salisbury, Margaret L. https://orcid.org/0000-0001-8217-6955
,
Funding

Funding for this research was provided by:

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.
License Information

Text and Data Mining valid from 2024-09-06

Version of Record valid from 2024-09-06
More Information

Article History

Received: 18 March 2024

Accepted: 20 August 2024

First Online: 6 September 2024

Declarations

:

: Julia F Söllner, Christian Hesslinger, Thomas B Leonard, Nina M Patel, Thomas Schlange, and Richard Vinisko are employees of Boehringer Ingelheim. Stefan Bentink is an employee of Staburo GmbH, which was contracted by Boehringer Ingelheim to conduct some of the analyses presented in this manuscript. Megan L Neely and Jamie L Todd are faculty members of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to coordinate the IPF-PRO/ILD-PRO Registry. Jamie L Todd also reports grants paid to her institution from AstraZeneca and CareDx and has participated on advisory boards for Altavant Sciences, Avalyn, Natera, Sanofi, Theravance. Margaret L Salisbury reports grants paid to her institution from the National Institutes of Health; consulting fees from Boehringer Ingelheim, Orinove Inc., Roche; payment for lectures from Boehringer Ingelheim; and reimbursement to attend an investigators’ meeting from Boehringer Ingelheim.

: The IPF-PRO Registry study obtained ethics approval at the data coordinating center (Duke Clinical Research Institute, Duke Institutional Review Board Protocol Number Pro00046131). The IPF-PRO Registry protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to enrollment at each site (listed in Online Resource 5).

: Informed consent was obtained from all individual participants included in the study.

: Not applicable.

Document is current

Any future updates will be listed below